Biopharmaceutical company Incyte (Nasdaq: INCY) has reported encouraging results from its Phase 3 STOP-HS clinical trials evaluating povorcitinib, an oral JAK1 inhibitor, for moderate to severe ...

Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...

Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...

On Monday, Incyte published the top-line results from two phase 3 trials of its povorcitinib, a treatment aimed at combating moderate to severe hidradenitis suppurativa (HS), also known as acne ...

As previously reported, Guggenheim downgraded Incyte (INCY) to Neutral from Buy and removed the firm’s previous $92 price target after the ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...

Important research news last week included UK pharma major AstraZeneca releasing encouraging results from the CALYPSO Phase ...

Incyte (INCY) reported positive results in the 75 mg povorcitinib dose in hidradenitis suppurativa, reporting 11% delta and 14% delta in ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...